Discounted Cash Flow Rating

Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Evolus, Inc. Common Stock (EOLS)

Pharmaceutical Preparations

https://www.evolus.com

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare, or commercial insurance. It generates product revenue from the sale of Jeuveau in the United States.

520 NEWPORT CENTER DRIVE, SUITE 1200
NEWPORT BEACH, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/08/2018

Market Cap

915,501,195

Shares Outstanding

57,150,000

Weighted SO

57,760,722

Total Employees

N/A

Upcoming Earnings

08/07/2024

Similar Tickers

COLL --.--%

PAHC --.--%

ANIP --.--%

PROC --.--%

SSIC --.--%

EGRX --.--%

DCPH --.--%

PBH --.--%

PCRX --.--%

Beta

1.2970

Last Div

0.0000

Range

7.44-15.433

Chg

0.9100

Avg Vol

483398

Mkt Cap

915501195

Exch

NASDAQ

Country

US

Phone

949 284 4555

DCF Diff

14.1005

DCF

-0.0525

Div Yield

0.0000

P/S

3.8700

EV Multiple

-28.4041

P/FV

47.1230

Div Yield %

0.0000

P/E

-17.1036

PEG

-0.9099

Payout

0.0000

Current Ratio

2.9220

Quick Ratio

2.6748

Cash Ratio

1.7309

DSO

66.5756

DIO

64.2184

Op Cycle

130.7940

DPO

49.3408

CCC

81.4532

Gross Margin

0.6785

Op Margin

-0.1351

Pretax Margin

-0.2240

Net Margin

-0.2249

Eff Tax Rate

-0.0042

ROA

-0.2276

ROE

92.5443

ROCE

-0.1779

NI/EBT

1.0042

EBT/EBIT

1.6579

EBIT/Rev

-0.1351

Debt Ratio

0.5217

D/E

6.3145

LT Debt/Cap

0.8623

Total Debt/Cap

0.8633

Int Coverage

-108.3492

CF/Debt

-0.4189

Equity Multi

12.1038

Rec Turnover

5.4825

Pay Turnover

7.3975

Inv Turnover

5.6837

FA Turnover

30.5401

Asset Turnover

1.0119

OCF/Share

-0.8146

FCF/Share

-0.8616

Cash/Share

1.4934

OCF/Sales

-0.2160

FCF/OCF

1.0578

CF Coverage

-0.4189

ST Coverage

-49.0807

CapEx Coverage

-17.3138

Div&CapEx Cov

-17.3138

P/BV

47.1230

P/B

47.1230

P/S

3.8700

P/E

-17.1036

P/FCF

-16.9399

P/OCF

-17.8133

P/CF

-17.8133

PEG

-0.9099

P/S

3.8700

EV Multiple

-28.4041

P/FV

47.1230

DPS

0.0000

Latest Headlines (EST)

No Headlines Found

Revenue Product Segmentation